Evidence map›Paper›PMID 39063193›Full record

ReviewInternational journal of molecular sciences2024

Role of IL-27 in COVID-19: A Thin Line between Protection and Disease Promotion.

Zoia R Korobova, Natalia A Arsentieva, Angela Santoni, Areg A Totolian

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zoia R KorobovaLaboratory of Molecular Immunology, Saint Petersburg Pasteur Institute, 197101 Saint Petersburg, Russia.ORCID 0000-0003-0535-5014
Natalia A ArsentievaLaboratory of Molecular Immunology, Saint Petersburg Pasteur Institute, 197101 Saint Petersburg, Russia.
Angela SantoniDepartment of Molecular Medicine, Pasteur Institute-Cenci Bolognetti Foundation, Sapienza University of Rome, 00162 Rome, Italy.
Areg A TotolianLaboratory of Molecular Immunology, Saint Petersburg Pasteur Institute, 197101 Saint Petersburg, Russia.ORCID 0000-0003-4571-8799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine storm is usually described as one of the main reasons behind COVID-associated mortality. Cytokines are essential protein molecules engaged in immune responses; they play a critical role in protection against infections. However, they also contribute to inflammatory reactions and tissue damage, becoming a double-edged sword in the context of COVID-19. Recent studies have suggested various cytokines and chemokines that play a crucial role in the immune response to SARS-CoV-2 infection. One such cytokine is interleukin 27 (IL-27), which has been found to be elevated in the blood plasma of patients with COVID-19. Within this study, we will explore the role of IL-27 in immune responses and analyze both the existing literature and our own prior research findings on this cytokine in the context of COVID-19. It affects a wide variety of immune cells. Regardless of the pathological process it is involved in, IL-27 is critical for upholding the necessary balance between tissue damage and cytotoxicity against infectious agents and/or tumors. In COVID-19, it is involved in multiple processes, including antiviral cytotoxicity via CD8+ cells, IgG subclass switching, and even the activation of Tregs.

Indexed as

COVID-19SARS-CoV-2CD8-Positive T-LymphocytesCytokine Release SyndromeHumansInterleukin-27InterleukinsT-Lymphocytes, RegulatoryInterleukin-27InterleukinsMYDGF protein, humancellular immunityCOVID-19cytokinesIL-27inflammation

Identifiers

PMID39063193
PMCPMC11276726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.